Skip to main content

Advertisement

Table 3 Differences of indexes in patients at different treatment periods

From: Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system

Index Baseline (mean ± SD) Post-treatment (mean ± SD) t/Z P
Group A: 3 months of full-dose anti-TNFα (n = 10; n = 6 for anti-TNFα alone, n = 4 for combination)a
 ASDAS 3.43 ± 1.55 1.66 ± 0.40 2.675 0.043
 SPARCC 31.67 ± 18.64 14.50 ± 18.41 3.768 0.012
 ESRb 52.00 ± 43.83 5.00 ± 5.55 –2.023 0.046
 CRPb 36.58 ± 40.37 1.92 ± 1.09 –1.782 0.083
Group B: 4–6 months of anti-TNFα (n = 17; n = 4 for anti-TNFα alone, n = 13 for combination)c
 ASDAS 2.46 ± 0.58 1.58 ± 0.69 4.920 <0.001
 SPARCC 34.98 ± 18.93 18.54 ± 15.72 4.285 0.001
 ESRb 27.77 ± 34.95 7.22 ± 12.31 –2.749 0.007
 CRPb 16.34 ± 23.11 4.37 ± 17.87 –2.283 0.025
Group C: 9–12 months of anti-TNFα (n = 12; n = 6 for anti-TNFα alone, n = 6 for combination)d
 ASDAS 2.91 ± 0.89 2.05 ± 1.21 2.517 0.042
 SPARCC 38.24 ± 15.39 23.09 ± 15.65 2.527 0.038
 ESRb 28.29 ± 27.77 12.43 ± 13.57 –1.498 0.128
 CRPb 14.43 ± 11.65 10.81 ± 16.54 –1.529 0.134
  1. aBaseline of clinical practices from patients in Group A: 85.7 % male; age, 23 ± 5.62; symptom duration, 2.6 ± 3.25; HLA-B27-positive, 85.7 %
  2. bNot normally distributed, compared by paired rank test
  3. cBaseline of clinical practices from patients in Group B: 85.7 % male; age, 23.3 ± 6.43; symptom duration, 3.15 ± 2.98; HLA-B27-positive, 100 %
  4. dBaseline of clinical practices from patients in Group C: 80 % male; age, 21.3 ± 2.53; symptom duration, 3.97 ± 3.52; HLA-B27-positive, 90 %
  5. ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SD standard deviation, SPARCC Spondyloarthritis Research Consortium Canada, TNFα tumor necrosis factor alpha